Reaction

Bilirubin Conjugated Increased reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,294 reports · 93 co-occurring drugs

As of the last recalculation, Bilirubin Conjugated Increased appears in 2,294 FAERS reports alongside 93 co-occurring drug terms. The strongest observed disproportionality signal is ATAZANAVIR (PRR 34.9).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Atazanavir	54	34.9	35.0
Pyrazinamide	22	21.4	21.5
Posaconazole Delayed-Release	23	19.2	19.2
Rifampicin	21	19.0	19.0
Isoniazid	31	17.6	17.6
Ribavirin	102	15.0	15.0
Pegaspargase	20	14.9	15.0
Mercaptopurine	28	14.8	14.8
Posaconazole	26	14.7	14.7
Ursosiol	31	14.7	14.7
Basiliximab	18	14.0	14.0
Phytonadione	13	14.0	14.0
Ursodiol	33	13.9	14.0
Vincristine Sulfate	44	13.9	13.9
Micafungin Sodium	12	12.9	12.9
Lopinavir And Ritonavir	18	12.1	12.2
Ganciclovir Sodium	14	12.1	12.1
Ganciclovir	13	11.6	11.6
Calcium Gluconate	15	11.4	11.4
Entecavir	14	10.9	11.0
Heparin Sodium	16	10.6	10.6
Ribociclib	36	10.5	10.5
Cytarabine	66	10.2	10.2
Deferasirox	29	10.0	10.0
Elexacaftor, Tezacaftor, And Ivacaftor	13	9.5	9.5
Rifampin	15	9.4	9.4
Methimazole	8	9.3	9.3
Voriconazole	30	9.1	9.1
Dextrose	13	9.0	9.0
Dextrose Monohydrate	13	8.9	8.9
Regorafenib	11	8.6	8.6
Bosentan	46	8.4	8.4
Lactulose	35	8.4	8.4
Linezolid	26	8.0	8.0
Sodium Bicarbonate	20	7.9	7.9
Sodium Bicarbonate Injection,	20	7.9	7.9
Magnesium Sulfate In Water For	11	7.8	7.9
Hydroxyurea	18	7.8	7.8
Magnesium Sulfate Heptahydrate	11	7.7	7.7
Magnesium Sulfate	11	7.7	7.7
Amikacin	14	7.5	7.5
Meropenem	26	7.4	7.4
Lamivudine	25	7.4	7.4
Diltiazem Hydrochloride Extended-Release Tablets	9	7.2	7.2
Levofloxacin	46	7.0	7.0
Levofloxacin In 5% Dextrose	46	7.0	7.0
Gentamicin Sulfate	12	6.9	6.9
Phenobarbital	11	6.9	6.9
Nilotinib	22	6.8	6.8
Fondaparinux Sodium	6	6.7	6.7
Voriconazole Injection	16	6.7	6.7
Dutasteride	6	6.7	6.7
Insulin	40	6.6	6.6
Sorafenib	15	6.6	6.6
Amphotericin B	9	6.5	6.5
Lamivudine Oral	18	6.5	6.5
Mycophenolic Acid	22	6.3	6.3
Dexamethasone Sodium Phosphate	7	6.3	6.3
Gentamicin	9	6.3	6.3
Dronedarone	7	6.2	6.2
Goserelin	9	6.1	6.1
Ritonavir 100 Mg	10	6.1	6.1
Tenofovir Disoproxil Fumarate	22	6.1	6.1
Enoxaparin Sodium	38	6.1	6.1
Ritonavir	19	5.9	5.9
Erlotinib Hydrochloride	8	5.8	5.8
Propofol	23	5.8	5.8
Atovaquone	5	5.6	5.6
Mesna Injection	5	5.5	5.5
Zidovudine	8	5.4	5.4
Mesna	5	5.4	5.4
Bleomycin Sulfate	6	5.3	5.3
Blinatumomab	6	5.2	5.2
Nevirapine	5	5.0	5.0
Eculizumab	29	4.9	4.9
Brentuximab Vedotin	5	4.4	4.4
Ado-Trastuzumab Emtansine	4	4.3	4.3
Crizotinib	6	4.3	4.3
Lapatinib	7	4.1	4.1
Remdesivir	6	4.1	4.1
Daptomycin	4	3.9	3.9
Macitentan	29	3.8	3.8
Peginterferon Alfa-2A	22	3.7	3.7
Gemcitabine	15	3.5	3.5
Gemcitabine Hydrochloride	20	3.4	3.4
Pazopanib Hydrochloride	10	3.4	3.4
Eltrombopag Olamine	8	3.2	3.2
Alpelisib	3	3.1	3.1
Vismodegib	3	3.1	3.1
Glecaprevir And Pibrentasvir	3	2.5	2.5
Atezolizumab	10	2.3	2.3
Dornase Alfa	5	2.3	2.3
Sofosbuvir	5	2.3	2.3

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.